Member (w)
Russell George Sir Drefaldwyn
WQ88512 (e) Wedi’i gyflwyno ar 23/06/2023

Pa gamau y mae Llywodraeth Cymru yn eu cymryd i gefnogi Pwyllgor Gwasanaethau Iechyd Arbenigol Cymru i sicrhau bod canolfannau triniaeth CAR-T yn cael eu hehangu ar gyfer cleifion ledled Cymru?

Wedi'i ateb gan Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol | Wedi'i ateb ar 04/07/2023

I recognise the importance of access to Advanced Therapeutic Medicinal Products (ATMPs) such as Chimeric Antigen Receptor T-cell (CAR-T) therapy. The Welsh Health Specialised Services Committee is responsible for commissioning this service on behalf of health boards in Wales.

The commissioning policies include equitable access and can be found at:

Specialised Services Policy Position: PP185

whssc.nhs.wales/commissioning/whssc-policies/cancer/chimeric-antigen-receptor-t-cell-car-t-therapy-policy-position-statement-pp185-april-2023/

Specialised Services Service Specification: CP176

whssc.nhs.wales/commissioning/whssc-policies/all-policy-documents/chimeric-antigen-receptor-t-cell-car-t-therapy-gilead-axicabtagene-ciloleucel-yescarta-service-specification-cp175-march-2019/

Specialised Services Service Specification: CP175

whssc.nhs.wales/commissioning/whssc-policies/all-policy-documents/chimeric-antigen-receptor-t-cell-car-t-therapy-novartis-tisagenlecleucel-kymriah-service-specification-cp176-march-2019/

The criteria for a unit to deliver CAR-T is described in these policies. There are no intentions at the present time to commission additional centres in Wales.